Lisa Kattenhorn
Research Subjects
Lisa Kattenhorn has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Marc R. Pelletier
Novartis Institutes for Biomedical Research, Cambridge, Massachusetts
26 shared publications - Angelo L. Grauel
Novartis Institutes for Biomedical Research 5 Cambridge
20 shared publications - Anna F. Farago
Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts
20 shared publications - Carlotta Costa
Mass. General Hospital Cancer Center, Charlestown, MA
20 shared publications - Claudia Bossen
Novartis Pharma
20 shared publications - Fanying Tang
Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts
20 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Supplementary tables and figures with legends
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Supplementary tables and figures with legends
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Purpose:The stimulator of IFN genes (STING) is a transmembrane protein that plays a role in the immune response to tumors. Single-agent STING agonist MIW815 (ADU-S100) has demonstrated immune activation but limited antitumor activity. This phase Ib, multicenter, dose-escalation study assessed the safety and tolerability of MIW815 plus spartalizumab (PDR001), a humanized IgG4 antibody against PD-1, in 106 patients with advanced solid tumors or lymphomas.Patients and Methods:Patients were treated with weekly intratumoral injections of MIW815 (50–3,200 μg) on a 3-weeks-on/1-week-off schedule or once every 4 weeks, plus a fixed dose of spartalizumab (400 mg) intravenously every 4 weeks.Results:Common adverse events were pyrexia (n = 23; 22%), injection site pain (n = 21; 20%), and diarrhea (n = 12; 11%). Overall response rate was 10.4%. The MTD was not reached. Pharmacodynamic biomarker analysis demonstrated on-target activity.Conclusions:The combination of MIW815 and spartalizumab was well tolerated in patients with advanced/metastatic cancers, including in patients with anti-PD-1 refractory disease. Minimal antitumor responses were seen.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Purpose:The stimulator of IFN genes (STING) is a transmembrane protein that plays a role in the immune response to tumors. Single-agent STING agonist MIW815 (ADU-S100) has demonstrated immune activation but limited antitumor activity. This phase Ib, multicenter, dose-escalation study assessed the safety and tolerability of MIW815 plus spartalizumab (PDR001), a humanized IgG4 antibody against PD-1, in 106 patients with advanced solid tumors or lymphomas.Patients and Methods:Patients were treated with weekly intratumoral injections of MIW815 (50–3,200 μg) on a 3-weeks-on/1-week-off schedule or once every 4 weeks, plus a fixed dose of spartalizumab (400 mg) intravenously every 4 weeks.Results:Common adverse events were pyrexia (n = 23; 22%), injection site pain (n = 21; 20%), and diarrhea (n = 12; 11%). Overall response rate was 10.4%. The MTD was not reached. Pharmacodynamic biomarker analysis demonstrated on-target activity.Conclusions:The combination of MIW815 and spartalizumab was well tolerated in patients with advanced/metastatic cancers, including in patients with anti-PD-1 refractory disease. Minimal antitumor responses were seen.
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Baseline gene expression with significant association with ICI treatment outcome (OS) in PD-L1 negative in both CANOPY-1 and Tempus cohort 1 patients
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Baseline gene expression with significant association with ICI treatment outcome (OS) in PD-L1 negative in both CANOPY-1 and Tempus cohort 1 patients
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Criteria to define post-ICI patients (n = 326) into acquired (n = 75) and primary resistance (n = 59) in Tempus cohort
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Criteria to define post-ICI patients (n = 326) into acquired (n = 75) and primary resistance (n = 59) in Tempus cohort
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Table of differentially expressed gene table in acquired resistance compared to treatment naïve cohort
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Table of differentially expressed gene table in acquired resistance compared to treatment naïve cohort
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Distribution of biopsy tissue sites comparing the treatment-naïve group (cohort 1) with the post-ICI group (cohort 2) in the left two panels and contrasting primary resistance with acquired resistance within cohort 2 in the right two panels
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Distribution of biopsy tissue sites comparing the treatment-naïve group (cohort 1) with the post-ICI group (cohort 2) in the left two panels and contrasting primary resistance with acquired resistance within cohort 2 in the right two panels
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
List of gene expression signatured
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
List of gene expression signatured
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Key patient characteristics of the five cohorts in the study
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Key patient characteristics of the five cohorts in the study
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Analysis of TME between pre- and post-ICI samples in patients with paired biopsies (Tempus cohort 3).
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Analysis of TME between pre- and post-ICI samples in patients with paired biopsies (Tempus cohort 3).
- Open Access
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Analysis of the TME after monochemotherapy in the Tempus cohort 3 and SU2C-NSCLC cohorts. A, Volcano plot of differential expression analysis for 12 patients treated with platinum-based chemotherapy within Tempus cohort 3. B, Box plot of IFNγ signature expression before and after platinum therapy in 12 patients with paired biopsies. C, Box plot of the IFNγ signature by prior platinum-based therapy history in the SU2C-NSCLC cohort. D, Schematic of PD-L1 IHC class switching observed in Tempus cohort 3 by treatment class (ICI vs. non-ICI).
- 30 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data
Analysis of the TME after monochemotherapy in the Tempus cohort 3 and SU2C-NSCLC cohorts. A, Volcano plot of differential expression analysis for 12 patients treated with platinum-based chemotherapy within Tempus cohort 3. B, Box plot of IFNγ signature expression before and after platinum therapy in 12 patients with paired biopsies. C, Box plot of the IFNγ signature by prior platinum-based therapy history in the SU2C-NSCLC cohort. D, Schematic of PD-L1 IHC class switching observed in Tempus cohort 3 by treatment class (ICI vs. non-ICI).